
Rocket Pharmaceuticals, Inc. – NASDAQ:RCKT
Rocket Pharmaceuticals stock price today
Rocket Pharmaceuticals stock price monthly change
Rocket Pharmaceuticals stock price quarterly change
Rocket Pharmaceuticals stock price yearly change
Rocket Pharmaceuticals key metrics
Market Cap | 1.20B |
Enterprise value | 1.04B |
P/E | -5.52 |
EV/Sales | N/A |
EV/EBITDA | -4.87 |
Price/Sales | N/A |
Price/Book | 2.36 |
PEG ratio | 0.24 |
EPS | -2.86 |
Revenue | N/A |
EBITDA | -251.30M |
Income | -249.31M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeRocket Pharmaceuticals stock price history
Rocket Pharmaceuticals stock forecast
Rocket Pharmaceuticals financial statements
$40.67
Potential upside: 1269.24%
Analysts Price target
Financials & Ratios estimates
Jun 2023 | 0 | -65.70M | |
---|---|---|---|
Sep 2023 | 0 | -61.89M | |
Dec 2023 | 10.31M | -59.66M | -578.55% |
Mar 2024 | 0 | -62.05M |
Jun 2023 | 461781000 | 58.81M | 12.74% |
---|---|---|---|
Sep 2023 | 598762000 | 57.67M | 9.63% |
Dec 2023 | 566341000 | 73.76M | 13.03% |
Mar 2024 | 499442000 | 57.94M | 11.6% |
Jun 2023 | -50.86M | 31.20M | 182K |
---|---|---|---|
Sep 2023 | -57.14M | 48.25M | 189.48M |
Dec 2023 | -29.33M | -140.80M | 391K |
Mar 2024 | -56.88M | 35.03M | 1.21M |
Rocket Pharmaceuticals alternative data
Aug 2023 | 240 |
---|---|
Sep 2023 | 240 |
Oct 2023 | 240 |
Nov 2023 | 240 |
Dec 2023 | 240 |
Jan 2024 | 240 |
Feb 2024 | 240 |
Mar 2024 | 268 |
Apr 2024 | 268 |
May 2024 | 268 |
Jun 2024 | 268 |
Jul 2024 | 268 |
Rocket Pharmaceuticals other data
Period | Buy | Sel |
---|---|---|
Jan 2024 | 0 | 638 |
Feb 2024 | 0 | 48318 |
Mar 2024 | 0 | 276490 |
Apr 2024 | 0 | 93365 |
May 2024 | 0 | 15963 |
Jul 2024 | 0 | 3838 |
Aug 2024 | 0 | 15730 |
Oct 2024 | 0 | 3997 |
Nov 2024 | 0 | 18078 |
Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
---|---|---|---|---|---|---|---|
Sale | MILITELLO JOHN officer: See Remarks | Common Stock | 1,224 | $13.05 | $15,978 | ||
Sale | PATEL KINNARI officer: See Remarks | Common Stock | 4,588 | $13.05 | $59,892 | ||
Sale | SHAH GAURAV director, officer.. | Common Stock | 11,091 | $13.05 | $144,782 | ||
Sale | WILSON MARTIN officer: General Counsel | Common Stock | 1,175 | $13.05 | $15,338 | ||
Sale | WHITE MARK ANDREW officer: See Remarks | Common Stock | 3,080 | $16.63 | $51,205 | ||
Sale | MILITELLO JOHN officer: See Remarks | Common Stock | 917 | $16.63 | $15,245 | ||
Sale | MILITELLO JOHN officer: See Remarks | Common Stock | 1,064 | $18.5 | $19,688 | ||
Sale | PATEL KINNARI officer: See Remarks | Common Stock | 3,989 | $18.5 | $73,812 | ||
Sale | SHAH GAURAV director, officer.. | Common Stock | 9,650 | $18.5 | $178,564 | ||
Sale | WILSON MARTIN officer: General Counsel | Common Stock | 1,027 | $18.5 | $19,004 |
Quarter | Transcript |
---|---|
Q2 2021 9 Aug 2021 | Q2 2021 Earnings Call Transcript |
Insider | Compensation |
---|---|
Dr. Gaurav D. Shah (1975) Chief Executive Officer & Director | $1,040,000 |
Ms. Kinnari Patel M.B.A., Pharm.D., PharmD, MBA (1979) Pres, Chief Operating Officer & Head of Devel. | $825,900 |
Mr. Jonathan Schwartz (1964) Chief Medical Officer & Senior Vice President of Clinical Devel. | $619,700 |
Mr. John C. Militello CPA, CPA (1973) Vice President, Senior Controller & Principal Accounting Officer | $385,780 |
Rocket Pharmaceuticals: Cautiously Optimistic (Rating Upgrade)
Rocket Pharmaceuticals: Multiple Regulatory Submissions Make It A Must Watch
Rocket Pharmaceuticals: Update On RP-A501 Strengthens Bullish Outlook
Rocket Pharmaceuticals: Soaring On Pivotal Danon Disease Study Agreement - More Upside Ahead?
Rocket Pharmaceuticals: Thriving Gene Therapy With Multiple Catalysts
Rocket Pharmaceuticals: A Catalyst-Rich Year Ahead
Rocket Pharmaceuticals: Promising Gene Therapy Play With Discounted Entry Point
Rocket Pharmaceuticals Has A Lot More Upside
Rocket Pharmaceuticals: 2 Regulatory Filings In 2023 Could Propel It Higher
-
What's the price of Rocket Pharmaceuticals stock today?
One share of Rocket Pharmaceuticals stock can currently be purchased for approximately $2.97.
-
When is Rocket Pharmaceuticals's next earnings date?
Unfortunately, Rocket Pharmaceuticals's (RCKT) next earnings date is currently unknown.
-
Does Rocket Pharmaceuticals pay dividends?
No, Rocket Pharmaceuticals does not pay dividends.
-
How much money does Rocket Pharmaceuticals make?
Rocket Pharmaceuticals has a market capitalization of 1.20B.
-
What is Rocket Pharmaceuticals's stock symbol?
Rocket Pharmaceuticals, Inc. is traded on the NASDAQ under the ticker symbol "RCKT".
-
What is Rocket Pharmaceuticals's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Rocket Pharmaceuticals?
Shares of Rocket Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Rocket Pharmaceuticals's key executives?
Rocket Pharmaceuticals's management team includes the following people:
- Dr. Gaurav D. Shah Chief Executive Officer & Director(age: 50, pay: $1,040,000)
- Ms. Kinnari Patel M.B.A., Pharm.D., PharmD, MBA Pres, Chief Operating Officer & Head of Devel.(age: 46, pay: $825,900)
- Mr. Jonathan Schwartz Chief Medical Officer & Senior Vice President of Clinical Devel.(age: 61, pay: $619,700)
- Mr. John C. Militello CPA, CPA Vice President, Senior Controller & Principal Accounting Officer(age: 52, pay: $385,780)
-
How many employees does Rocket Pharmaceuticals have?
As Jul 2024, Rocket Pharmaceuticals employs 268 workers.
-
When Rocket Pharmaceuticals went public?
Rocket Pharmaceuticals, Inc. is publicly traded company for more then 10 years since IPO on 18 Feb 2015.
-
What is Rocket Pharmaceuticals's official website?
The official website for Rocket Pharmaceuticals is rocketpharma.com.
-
Where are Rocket Pharmaceuticals's headquarters?
Rocket Pharmaceuticals is headquartered at 9 Cedarbrook Drive, Cranbury, NJ.
-
How can i contact Rocket Pharmaceuticals?
Rocket Pharmaceuticals's mailing address is 9 Cedarbrook Drive, Cranbury, NJ and company can be reached via phone at +60 9 659 8001.
-
What is Rocket Pharmaceuticals stock forecast & price target?
Based on 2 Wall Street analysts` predicted price targets for Rocket Pharmaceuticals in the last 12 months, the avarage price target is $40.67. The average price target represents a 1269.24% change from the last price of $2.97.
Rocket Pharmaceuticals company profile:

Rocket Pharmaceuticals, Inc.
rocketpharma.comNASDAQ
268
Biotechnology
Healthcare
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure. It has license agreements with Fred Hutchinson Cancer Research Center; Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; CIEMAT and UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. is headquartered in Cranbury, New Jersey.
Cranbury, NJ 08512
CIK: 0001281895
ISIN: US77313F1066
CUSIP: 77313F106